Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia

This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

Inclusion Criteria:

• Levemir® above 6 yrs
• NovoMix® 30 above 18 yrs
• Patients with Type 1 or Type 2 diabetes, including newly diagnosed

Exclusion Criteria:

• Current treatment with NovoMix® 30 or Levemir®